Target Information

Target General Infomation
Target ID
T44791
Former ID
TTDI01747
Target Name
VEGF ligand
Target Type
Clinical Trial
Disease Age related macular degeneration [ICD9: 362.5; ICD10: H35.3]
Cancer [ICD9: 140-229; ICD10: C00-C96]
Diabetic macular edema [ICD9: 250, 362.01, 362.07, 362.53, 782.3; ICD10: E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9]
Macular degeneration [ICD9: 362.5; ICD10: H35.3]
Drugs and Mode of Action
Drug(s) Squalamine Drug Info Phase 3 Cancer [521667]
ALG-1001 Drug Info Phase 2 Diabetic macular edema [550226]
AVA-101 Drug Info Phase 2 Age related macular degeneration [549343]
TG100801 Drug Info Phase 2 Macular degeneration [522077]
NM-3 Drug Info Phase 1 Cancer [521536]
PF-06439535 Drug Info Phase 1 Cancer [524593]
Modulator ALG-1001 Drug Info [533188]
AVA-101 Drug Info [550307]
Squalamine Drug Info [551462]
Inhibitor NM-3 Drug Info [528167]
TG100801 Drug Info [529366]
References
Ref 521536ClinicalTrials.gov (NCT00046696) A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health.
Ref 521667ClinicalTrials.gov (NCT00139282) A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration. U.S. National Institutes of Health.
Ref 522077ClinicalTrials.gov (NCT00509548) Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD. U.S. National Institutes of Health.
Ref 524593ClinicalTrials.gov (NCT02031991) A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01). U.S. National Institutes of Health.
Ref 549343Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035470)
Ref 550226Clinical pipeline report, company report or official report of Allegro Ophthalmics.
Ref 5281672-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes. 2006 May;55(5):1232-42.
Ref 529366Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37.
Ref 533188Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:138070.
Ref 550307Clinical pipeline report, company report or official report of Avalanche Biotechnologies.
Ref 550401National Cancer Institute Drug Dictionary (drug id 43234).
Ref 551462Clinical pipeline report, company report or official report of Ohr Pharmaceutical.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.